We previously published the BEAT-lupus trial, a placebo-controlled clinical trial comparing treatment with rituximab with or without the BAFF inhibitor belimumab in patients with SLE refractory to conventional therapy.6 This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.